GH
NEUTRAL
$87.17
Live
Guardant Health, Inc. · NASDAQ
Target $129.73
(+48.8%)
$36.36
52W Range
$120.74
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 10, 2026
Market cap
$11.43B
P/E
N/A
ROE
N/A
Profit margin
-42.4%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
Guardant Health presents a classic high-growth, pre-profitability profile, evidenced by a stable but mediocre Piotroski F-Score of 4/9. While the company demonstrates impressive top-line momentum with 39.4% YoY revenue growth and a strong current ratio of 4.84, it continues to operate with significant negative margins and negative shareholder equity. The stark divergence between the 'Strong Buy' analyst consensus and the bearish insider selling suggests a disconnect between institutional growth projections and internal sentiment. Overall, the stock is a speculative growth play where valuation is driven by future market penetration rather than current fundamental value.
Key Strengths
Strong revenue growth (39.4% YoY)
Excellent short-term liquidity (Current Ratio 4.84)
Robust gross margins (64.46%) indicating strong product pricing power
Consistent history of beating earnings estimates in recent quarters
Strong analyst support with a target price of $129.73
Key Risks
Significant negative profitability (Operating Margin -42.91%)
Negative shareholder equity (Price/Book -114.70)
Bearish insider activity with recent sales by the CFO and Directors
High valuation multiple (Price/Sales 11.64) for a non-profitable entity
Negative technical trend and recent short-term price decline
AI Fair Value Estimate
Based on comprehensive analysis
$112.5
+29.1% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
42
Moderate
20
85
60
45
0
AI Verdict
Speculative Growth
Key drivers: Revenue acceleration, Liquidity position, Lack of net income, Insider selling
Confidence
80%
Value
20/100
Graham Number is N/A due to negative earnings; valuation is purely growth-based.
Positives
- Trading below analyst target price
Watchpoints
- Negative P/E
- Extreme negative Price/Book
- High P/S ratio
Future
85/100
Growth rates are the primary driver of the current stock price.
Positives
- 39% YoY revenue growth
- Strong analyst target ($129.73)
- Improving EPS trajectory
Watchpoints
- Path to profitability remains long
Past
60/100
Recent 1-year performance is strong, but long-term recovery is still underway.
Positives
- 1Y return of +98.7%
- Consistent revenue scaling
Watchpoints
- 5Y change is -43.8%
- Long history of EPS misses in early years
Health
45/100
High liquidity offsets the lack of profitability, but the balance sheet is structurally weak.
Positives
- Very high Current and Quick ratios
Watchpoints
- Piotroski F-Score of 4/9 (Stable but not strong)
- Negative ROA (-15.58%)
- Negative equity
Dividend
0/100
Company is in a growth phase and does not distribute capital.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$87.17
Analyst Target
$129.73
Upside/Downside
+48.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GH and closest competitors.
Updated 2026-04-09
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GH
Guardant Health, Inc.
Primary
|
-43.8% | +265.0% | +98.7% | +33.6% | -3.7% | -7.1% |
|
ALGN
Align Technology, Inc.
Peer
|
-70.6% | -48.8% | +2.3% | +24.8% | -16.9% | -5.6% |
|
EXEL
Exelixis, Inc.
Peer
|
+91.2% | +119.8% | +29.5% | +14.4% | +4.3% | +0.4% |
|
ENSG
The Ensign Group, Inc.
Peer
|
+121.6% | +109.3% | +65.7% | +16.2% | -2.4% | +2.3% |
|
BMRN
BioMarin Pharmaceutical Inc.
Peer
|
-27.4% | -41.9% | -20.1% | +4.3% | -5.4% | +4.4% |
GH
Guardant Health, Inc.
Primary
5Y
-43.8%
3Y
+265.0%
1Y
+98.7%
6M
+33.6%
1M
-3.7%
1W
-7.1%
ALG
Align Technology, Inc.
Peer
5Y
-70.6%
3Y
-48.8%
1Y
+2.3%
6M
+24.8%
1M
-16.9%
1W
-5.6%
EXE
Exelixis, Inc.
Peer
5Y
+91.2%
3Y
+119.8%
1Y
+29.5%
6M
+14.4%
1M
+4.3%
1W
+0.4%
ENS
The Ensign Group, Inc.
Peer
5Y
+121.6%
3Y
+109.3%
1Y
+65.7%
6M
+16.2%
1M
-2.4%
1W
+2.3%
BMR
BioMarin Pharmaceutical Inc.
Peer
5Y
-27.4%
3Y
-41.9%
1Y
-20.1%
6M
+4.3%
1M
-5.4%
1W
+4.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-140.56
PEG Ratio
N/A
P/B Ratio
-114.7
P/S Ratio
11.64
EV/Revenue
12.16
EV/EBITDA
-30.12
Market Cap
$11.43B
Profitability
Profit margins and return metrics
Profit Margin
-42.39%
Operating Margin
-42.91%
Gross Margin
64.46%
ROE
N/A
ROA
-15.58%
Growth
Revenue and earnings growth rates
Revenue Growth
+39.4%
Earnings Growth
N/A
Q/Q Revenue Growth
+39.37%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
4.84
Strong
Quick Ratio
4.42
Excellent
Cash/Share
$9.16
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.3B
Gross Margin
64.6%
Op. Margin
-43.0%
Net Margin
-45.7%
Total Assets
$2.0B
Liabilities
$2.1B
Equity
$-0.1B
Debt/Equity
-21.28x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
206%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-29
$N/A
2026-02-19
$-0.5
-6.5% surprise
2025-10-29
$-0.39
+20.3% surprise
2025-07-30
$-0.44
+14.5% surprise
Healthcare Sector Comparison
Comparing GH against 205 companies in the Healthcare sector
(17 bullish, 70 neutral, 118 bearish)
Profit Margin
-42.39%
This Stock
vs
-18.49%
Sector Avg
+129.2%
(Superior)
Revenue Growth
39.4%
This Stock
vs
106.86%
Sector Avg
-63.1%
(Slower)
Current Ratio
4.84
This Stock
vs
3.53
Sector Avg
+37.0%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GH
Guardant Health, Inc.
|
NEUTRAL | $11.43B | - | -% | -42.4% | $87.17 | |
|
ALGN
Align Technology, Inc.
|
NEUTRAL | $11.78B | 29.07 | 10.4% | 10.2% | $164.23 | Compare |
|
EXEL
Exelixis, Inc.
|
BULLISH | $11.85B | 15.84 | 35.5% | 33.7% | $44.2 | Compare |
|
ENSG
The Ensign Group, Inc.
|
NEUTRAL | $11.96B | 34.36 | 16.9% | 6.8% | $204.79 | Compare |
|
BMRN
BioMarin Pharmaceutical Inc.
|
NEUTRAL | $10.86B | 32.28 | 5.9% | 10.8% | $56.49 | Compare |
GH
Guardant Health, Inc.
NEUTRAL
Mkt Cap
$11.4B
P/E
-
ROE
-%
Price
$87.17
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | MONROE TERILYN J | Officer | Sale | 3,832 | $355,150 |
| 2026-04-01 | BELL MICHAEL BRIAN | Chief Financial Officer | Stock Award | 12,777 | - |
| 2026-04-01 | SAIA JOHN GOMES | Officer | Stock Award | 11,461 | - |
| 2026-04-01 | TALASAZ AMIRALI | Chief Executive Officer | Stock Award | 36,530 | - |
| 2026-04-01 | ELTOUKHY HELMY A | Chief Executive Officer | Stock Award | 36,530 | - |
| 2026-04-01 | EAGLE CRAIG | Officer | Stock Award | 11,400 | - |
| 2026-04-01 | MONROE TERILYN J | Officer | Stock Award | 8,019 | - |
| 2026-04-01 | FREEMAN CHRIS | Officer | Stock Award | 11,213 | - |
| 2026-04-01 | KALIA KUMUD | Chief Technology Officer | Stock Award | 10,044 | - |
| 2026-04-01 | CHUDOVA DARYA | Chief Technology Officer | Stock Award | 13,029 | - |
| 2026-03-31 | KROGNES STEVE E | Director | Stock Award | 155 | - |
| 2026-03-20 | MIGNONE ROBERTO A. | Director | Stock Award | 264 | - |
| 2026-03-18 | TARIQ MUSA | Director | Sale | 348 | $30,655 |
| 2026-03-17 | HIDALGO MEDINA MANUEL | Director | Stock Award | 232 | - |
| 2026-03-16 | BELL MICHAEL BRIAN | Chief Financial Officer | Sale | 3,000 | $261,111 |
MONROE TERILYN J
Officer
2026-04-06
3,832 shares
·
$355,150
BELL MICHAEL BRIAN
Chief Financial Officer
2026-04-01
12,777 shares
SAIA JOHN GOMES
Officer
2026-04-01
11,461 shares
TALASAZ AMIRALI
Chief Executive Officer
2026-04-01
36,530 shares
ELTOUKHY HELMY A
Chief Executive Officer
2026-04-01
36,530 shares
EAGLE CRAIG
Officer
2026-04-01
11,400 shares
MONROE TERILYN J
Officer
2026-04-01
8,019 shares
FREEMAN CHRIS
Officer
2026-04-01
11,213 shares
KALIA KUMUD
Chief Technology Officer
2026-04-01
10,044 shares
CHUDOVA DARYA
Chief Technology Officer
2026-04-01
13,029 shares
KROGNES STEVE E
Director
2026-03-31
155 shares
MIGNONE ROBERTO A.
Director
2026-03-20
264 shares
TARIQ MUSA
Director
2026-03-18
348 shares
·
$30,655
HIDALGO MEDINA MANUEL
Director
2026-03-17
232 shares
BELL MICHAEL BRIAN
Chief Financial Officer
2026-03-16
3,000 shares
·
$261,111
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
22 analysts
Evercore ISI Group
2026-04-06
In-Line
In-Line
Piper Sandler
2026-02-24
Overweight
Overweight
Leerink Partners
2026-02-20
Outperform
Outperform
Citigroup
2026-02-20
Buy
Buy
Canaccord Genuity
2026-02-20
Buy
Buy
JP Morgan
2026-02-20
Overweight
Overweight
TD Cowen
2026-02-20
Buy
Buy
Wells Fargo
2026-02-20
Overweight
Overweight
Stifel
2026-02-20
Buy
Buy
Evercore ISI Group
2026-02-20
In-Line
In-Line
Past News Coverage
Recent headlines mentioning GH from our newsroom.
Newest → oldest
No matching news yet.